Summary & Overview
HCPCS Level II J3120: Testosterone Enanthate Injection, up to 100 mg
HCPCS Level II code J3120 denotes administration of testosterone enanthate, up to 100 mg, delivered as an intramuscular injection. Nationally, this code is used to capture services for androgen replacement and certain hormone therapy indications where injectable testosterone is clinically indicated. Proper coding of injectable testosterone matters for clinical documentation, payer adjudication, and supply chain tracking.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of coding conventions for J3120, typical sites of service, and the clinical context for testosterone enanthate use. The publication also summarizes benchmarking elements and policy-relevant updates that affect billing and coverage for injectable testosterone products.
This summary is aimed at billing managers, revenue cycle staff, and clinicians who need concise reference material on HCPCS Level II code J3120, including practical notes on where the service is commonly delivered and why accurate coding is important for national reporting and payer communication.
Billing Code Overview
HCPCS Level II code J3120 represents an injection of testosterone enanthate, up to 100 mg. This code describes a medication administration service for intramuscular testosterone enanthate intended for hormone therapy or androgen replacement.
-
Service type: Medication injection (intramuscular hormone therapy)
-
Typical site of service: Outpatient clinic, physician office, or other ambulatory care settings where intramuscular injections are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult male presenting to an outpatient endocrinology clinic for testosterone replacement therapy due to symptomatic hypogonadism. The patient reports low libido, fatigue, decreased muscle mass, and laboratory-confirmed low serum total testosterone on two morning samples. The clinician reviews contraindications, documents informed consent, calculates an appropriate starting dose, and orders intramuscular testosterone enanthate administered up to 100 mg per injection on a scheduled interval (commonly weekly or every 1–2 weeks depending on regimen).
The clinical workflow includes: review of history and prior labs; review of cardiovascular risk factors and prostate screening (PSA) as clinically indicated; counseling on expected effects and adverse events; medication order entry for J3120; nursing preparation of the medication; administration via intramuscular injection (typically into the deltoid or gluteal muscle) in the clinic or infusion/medication administration area; post-injection observation for immediate adverse reaction; documentation of lot number, dose, site, and patient's response in the medical record; scheduling of follow-up visits and repeat testosterone levels to titrate dosing.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
24 | Unrelated Evaluation and Management Service by the Same Physician During a Postoperative Period |